Outcome Resources Inc.

1-866-877-2053

Pharmacy Benefits Management

Pathways to Success Hospice Conference

 

The Hospice Clinician Blog

Subscribe to Blog:

Search:



ABH Gel  Abilify  ACA  Acetaminophen  acetaminophen  acid suppression. ranitidine  aclidinium bromide  acute phosphate nephropathy  Adult Failure to Thrive  Advair  adverse drug events  Affordable Care Act  Agitation  albuterol  aliskiren  allergy  alprazolam  Alzheimer's  Alzheimers  Ambien  Amitiza  and Methadone (Dolophine)  Angina  anorexia  anoro ellipta  antibiotics  Anticholinergics  anticoagulation  Antidepressant  antidepressant  antidepressants  antiplatelet  antipsychotic  antipsychotics  anxiety  appetite  appetite stimulant  Arcapta Neohaler  Aricept  arrhythmia  aspirin  asthma  Ativan  Avastin  Avinza  Azithromycin  azithromycin  Baclofen  barbiturates  Beers Criteria  Beers List  Benzodiazepines  benzodiazepines  Beta‐2 Agonists  bexarotene  bone metastases  bone pain  Boniva  bowel movement  breakthrough pain  Breo Ellipta  breo ellipta  Brintellix  brintellix  brochodilator  bronchodilator  Buprenorphine  BuprenorphinePranay Parihar  cancer pain  Cardiac Arrhythmia  cardiovascular  Celebrex  Celexa  Chlorpromazine (Thorazine)  cholinesterase inhibitors  Choosing Wisely  Cimetidine  CitAD  Citalopram  citalopram  Citalopram (Celexa)  CMS  codeine  colace  Combivent  Combivent Respimat  Comfort Kit  Compazine  compliance  compounded medication  Compro  constipation  contact hours  continuing education  controlled prescriptions  controlled substance  COPD  Coronary Artery Disease  corticosteroid  Coumadin  counterfeit drugs  CR 8358  dabigatran  Darvocet  Darvon  DEA  Debility  Delirium  delirium  dementia  depression  desvenlafaxine  Dexilant  Diazepam  docusate  Dopamine Antagonist  Dopamine Antagonist Antiemetics  Doxepin  drug disposal  drug shortage  drug shortages  dry powder inhaler  dyspnea  E-Kit  Edluar  Education  Endo  Endocet  Endodan  enema  escitalopram  Escitalopram (Lexapro)  esophagitis  eszopiclone  ethics  Evzio  Exalgo  Exelon  famotidine  faxing prescriptions  FDA  FDA REMS  fentanyl  fentanyl sublingual spray  fetzima  first-generation antihistamines  fleet enema  flu vaccine  fungal infection  Gastroesophageal reflux disease  Gastrointestinal  generic  generic drug  generic Lexapro  generic medication  generic Seroquel  generics  GERD  H2RA  Haldol  Haloperidol  haloperidol  Haloperidol (Haldol)  Heart  Heart Failure  HELP Hospice Act  hiccups  HIS  hospice  Hospice Action Network  hospice advocacy  hospice ceu  hospice clinical  hospice clinical support  Hospice Compliance  hospice compliance  hospice Conditions of Participation  hospice conference  hospice constipation  hospice COP  hospice CoP compliance  hospice cough  Hospice Diagnosis  hospice docusate  hospice drug  hospice drug choice  hospice drug disposal  hospice drug dosage  Hospice Drugs  hospice drugs  hospice drugs,delirium,haloperidol,haldol,antipsychotics  hospice education  hospice education programs  Hospice Item Set  hospice medication  Hospice Medication Chart  hospice medication disposal  hospice medication orders  hospice medication review  hospice medication reviews  Hospice Medications  hospice medications  hospice methadone  hospice opioid  hospice opioid conversion  hospice opioids  hospice pain management  hospice patient  hospice patient care  hospice patient discharge  hospice payment reform  hospice PBM  hospice pbm  hospice PBM choice  hospice pharmacist  hospice pharmacy  hospice pharmacy benefit manager  hospice pharmacy claim reporting  hospice pharmacy decision  hospice seizure  hospice symptom management  hospira carpuject  Hydrocodone  hydrocodone  hydrocodone/APAP  hydrocodone/APAP recall  hydromorphone  hydromorphone recall  hypoglycemics  IBS  incomplete cross-tolerance  influenza  Inhaled Corticosteroids  inhaler  inhaler technique  INR  Insomnia  insomnia  Intermezzo  ipratropium  irritable bowel  Kadian  Kaleo  ketamine  Ketoconazole  kidney disease  laxative  Lazanda  leg cramps  leukotriene-receptor antagonist  Linaclotide  Lipitor  long acting opioids  Lorazepam  Lortab  lovastatin drug interactions  low dose aspirin  LTRA  Lubiprostone  Lundbeck and Takeda  Lunesta  lung cancer  Lyrica  medical marijuana  Medicare  Medicare Hospice Benefit  Medicare Part D  medication adherence  medication allergy  medication disposal  medication errors  medication orders  medication review  medication shortage  medication tapering  Megace  Meningitis  meperidine  metered dose inhaler  Methadone  methadone dosage  Methylprednisolone  methyphenidate  Metoclopramide  Midazolam  morphine  morphine injection recall  morphine sulfate  multiple sclerosis  muscle relaxants  Naloxone HCl injection  Namenda  naproxen  narcotic  Nausea  nausea  NDC  Nexium  NHPCO  Nitrate  nitrofurantoin  Nitroglycerin  Nizoral  non-specific hospice diagnoses  NSAID  OIG  olanzapine  omeprazole  ondansetron hydrochloride  Opana  Opana ER  Opioid  opioid  opioid allergy  opioid disposal  opioid induced constipation  Opioid Overdose  opioid-induced constipation  opioids  overactive bladder  Oxybutynin  Oxycodone  oxycodone  oxycodone/APAP  Oxycontin  oxycontin  oxymorphone  oxytrol  palliative care  Parkinson's  Part D  Part D Prior Authorization  Pathways to Success Conference  patient compliance  PBM decision  pediatric  pediatric end of life care  pediatric hospice  pediatric hospice care  pediatric palliative  pediatric palliative care  pediatric palliative symptom management  Pepcid  peptic ulcer disease  Percocet  Percodan  Personalize Your Care Act  Phenadoz  Phenergan  PPI  PPIs  Pradaxa  Prochlorperazine  Product Information  Promethazine  Promethegan  Propoxyphene  Prostate Cancer  Proton Pump Inhibitor  Proton Pump Inhibitors  pruritis  QT interval  QT Prolongation  quetiapine  quinine  Recall  Reglan  Relistor  renal impairment  research  resperidone  respiratory medications  Revatio  Risperidone  risperidone  Roflumilast  Ropinirole  Salonpas  Sativex  Schedule II  schedule II medications  scheduled medications  Scopolamine  Selective Serotonin Reuptake Inhibitor  sennosides  Seroquel  Seroquel XR  Silenor  Singulair  Skilled Nursing Facility  Sonata  Spiriva  Sprix  SSRI  START and STOPP  statins liver function  statins safety  statins side effects  Steroid  stool softener  stroke  Sublingual Nitroglycerin  subsys  sulfa allergy  Symbicort  Tagamet  Targretin  targretin  TdP  tertiary TCAs  tiotropium  TIRF REMS Access Program  Transderm Scop  transmucosal immediate-release fentanyl  trazadone  Tudorza Pressair  Tylenol  tylenol  Valium  Versed  Vicodin  vicodin  viibryd  vilazodone  vitamin K  vortioxetine  warfarin  Wound Care  writing orders  zaleplon  Zantac  zithromax  Zofran  zogenix  zohydro  Zolpidem  zolpidem  Zolpimist  Zydone  Zyprexa 

06/30/2014

Hospice Item Set (HIS) - CMS Quality Data Collection Starts on July 1st 2014

Esther Liu, PharmD, MSIA, CGP

HIS is a patient-level data collection tool developed as part of the Hospice Quality Reporting Program (HQRP), which can be used to collect data to calculate 6 National Quality Forum-endorsed (NQF) Measures and 1 modified NQF Measure. See below for a list of measures required:

1. NQF #1617 Patients Treated with an Opioid who are Given a Bowel Regimen
2. NQF #1634 Pain Screening
3. NQF #1637 Pain Assessment
4. NQF #1638 Dyspnea Treatment
5. NQF #1639 Dyspnea Screening
6. NQF #1641 Treatment Preferences
7. Modified NQF #1647 Beliefs/Values Addressed (if desired by the patient)

HIS is implemented as part of the FY 2014 Hospice Wage Index Final Rule issued last year in July 2013. To refresh your mind regarding HIS submission, you may visit the CMS website to view the training materials. CMS requires ALL Medicare-certified hospices to submit HIS data on ALL patients. Please be aware of the completion and submission deadlines. Data collection of HIS for each admission must be completed within 14 days and submitted to CMS within 30 days after admission. Data collection for HIS for discharged patients must be completed within 7 days and submitted to CMS within 30 days after discharge.  If the hospice failed to be compliant in reporting patient admission/discharge data, this would impact its payment rate in fiscal year of 2016.

As a Pharmacy Benefit Manager, we help our hospice partners to collect data to fulfil HIS requirements related to medications. To learn about the different reporting tools we offer to our partners, please contact the clinical department at clinical AT outcomeresources DOT com or Submit Your Information and we will contact you directly.




06/27/2014

Hospice Medication Alert: New PPI Available OTC - Nexium 24HR

Jennifer Chen, PharmD

On March 28th, FDA approved the over-the-counter Nexium 24HR (esomeprazole magnesium) 20mg delayed-release capsules. Nexium is part of a class of drugs called proton pump inhibitors (PPIs), which is commonly used for gastroesophageal reflux disease (GERD), erosive esophagitis and prevention of NSAID-induced gastric ulcers. This purple pill, previously available by prescription only, is now available over-the-counter providing patients who suffer from frequent heartburn an easier access.

However, Nexium 40mg delayed-release capsules still remains available by prescription only as well as other formulations of Nexium including Nexium I.V. and Nexium oral suspension. For patients with difficulty swallowing, the Nexium 24HR capsule can be opened and mixed in applesauce.

The status change to OTC does not take away its potential harms. Its side effects include headache, diarrhea, increased infection and bone fractures. In general, short-term use of PPI is safe. The approved OTC labeling is a 14-day treatment and may be repeated every 4 months.

As mentioned in a previous article, Nexium was the number 2 drug in “Top 100 Drugs by Sales” over the past year. The cost for Nexium 24HR is significantly lower than the prescription version (about 1/10th the cost of prescription Nexium). The OTC availability of Nexium 24HR provides another cost-effective alternative for hospice patients. Other PPIs available in OTC formulations are Prevacid (lansoprazole) and Prilosec (omeprazole).




06/26/2014

Medication Errors: The Problem of Look-Alike, Sound-Alike Drug Names

Jim Joyner, PharmD, CGP

One of the most common sources of medication errors is the problem of “look-alike” and/or “sound alike” drug names.  The risk for serious errors can arise when medication orders or prescriptions are not written clearly and the reader misinterprets the intended drug for a different drug with a very similar spelling.  Another variation on this error theme is when a drug name is transmitted verbally (either directly or more likely, over the phone) which sounds very similar to a different drug.  The listener may hear a different drug name than that which was intended.  There are very many drugs that fit into these categories of look-alike and sound alike drugs, providing the clinician with a great many opportunities for misinterpretation. This table provides just a few examples. (You may wish to share this with your staff.)

There are a number of ways to reduce the risk for this type of error through increased clinician awareness of the problem, coupled with a variety of safe practices.  Here are a few safe practices that are worth consideration:
  
• Put the drug name that you heard or read into the context of the overall medication order; does the strength, frequency for use, and reason for use make sense for the drug name? 

• Know what the medication is intended to be used for.  Is the drug name that you heard indicated or commonly used for managing that type of condition or symptom?

• If the person transmitting the order verbally is not clear or has an accent that you are not familiar with, ask them to spell it out. 

• When initiating an order in writing or verbally, consider using both the brand name AND generic name.

• When initiating an order, consider including the “reason for use” in the medication order.    Such as “for depression” or “for arthritis”.

• When selecting drug line items from a computer data-base, keep in mind that look-alike drug names may appear consecutively in the list, making the incorrect selection a high probability.  Double – check all selections for accuracy against the intended drug name.  

• Some computerized drug data bases can be configured to change the appearance of look-alike drug names to draw attention to their dissimilarities.  This is done with the use of “tall man” (mixed case) lettering. 

• Develop a working knowledge of actual look-alike and sound-alike drug names.  The Institute for Safe Medication Practices (ISMP) has a very extensive list of drug name pairs that have been reported as error related events of this type.  The ISMP list is updated every few months.  Refer to http://ismp.org for more information on this topic and other medication error issues.  

Photo Credit

 

More information:
http://marketing.outcomeresources.com/acton/attachment/4185/f-018a/1/-/-/-/-/Commonly%20Used%20Look%20Alike%20Sound%20Alike%20Medications.pdf


06/23/2014

Hospice Legislative Update: The 2014 HAN Advocacy Intensive

Outcome Resources considered it an honor to recently sponsor the 2014 Hospice Action Network Advocacy Intensive in Washington, D.C. Together with over 200 hospice professionals we had the opportunity to share our hospice stories with nearly all of the nation’s Senators and State Representatives. In addition, this year, twenty advocates whose hospice programs would otherwise be unable to afford it were able to attend the Hospice Action Network’s Advocacy Intensive thanks to Outcome Resources scholarships. It is vital to bring these stories to Congress and have our voices heard on Capitol Hill.

The support of our elected officials is crucial to protect and preserve the hospice Medicare Benefit and to support legislation that positively affects those patients and families facing end of life. We are grateful to the Hospice Action Network for providing all of us involved in hospice the forum and opportunity to speak with a unified message in support of our daily efforts. During the meetings on the Hill with Representatives, Senators, and Legislative Assistants, this year advocates focused on requesting support with the issue of Hospice and Medicare Part D. (Learn more in our previous blog post about the issue.) As you may be aware, CMS issued guidance to the Part D provider and hospice communities introducing a “prior authorization” process for how the two groups should determine who pays for which drugs once a patient elects hospice. Since there is no uniform process in place, hospices are dealing with multiple Part D prior authorization processes and paperwork that in many cases requires the addition of staff, and patients are trapped in the middle of this confusing process – sometimes even deciding to disenroll from hospice or being left without medications.

To learn more about these issues or how you can help, please visit Hospice Action Network. You can also participate by calling your members of Congress. Outcome Resources has been involved as hospice advocates for many years and will continue to support these efforts at every opportunity. We are honored to have Jonathan Keyserling, Senior Vice President, Office of Health Policy and Counsel at the National Hospice and Palliative Care Organization presenting a session on Hospice Advocacy at the Outcome Resources Pathways to Success Conference by the Bay this November. To learn more about the Conference, visit the Conference Website or Download the Information Sheet.

View our photos of the HAN Advocacy Intensive on Facebook at http://on.fb.me/1m4GXvz.




06/05/2014

Update on High Cost Drugs In Hospice

Dr. Jim Joyner, PharmD, CGP

A recent article appeared in the Medscape News on-line site which presented the “Top 100 Drugs by Sales” over the past year. All of these drugs were brand-name products. The drugs made the list through a combination of two factors; popularity among prescribers and having a high cost. Thirteen of the drugs on this list are drugs that we see routinely prescribed for hospice patients to varying degrees. In light of limited hospice reimbursement rates and extremely tight budgets, it is appropriate for hospice organizations to evaluate current usage of these highly prescribed, high cost drugs. The remainder of this article will identify these drugs and discuss possible cost-effective alternatives.  

First, the 13 drugs are presented here with corresponding reported $ sales figures for the past year  (April 2013 – March 2014). Drugs are ranked from highest sales dollars to lowest:

Drug   Sales in billions
Abilify              6.9
Nexium           6.3
Advair              5.1
Spiriva             3.1

                                                                                         Lyrica               2.6
                                                                                         Oxycontin        2.5
                                                                                         Celebrex         2.3
                                                                                         Namenda       1.9
                                                                                         Symbicort       1.7
                                                                                         Seroquel XR  1.3
                                                                                         Dexilant           1.0
                                                                                         Lunesta           0.9
                                                                                         Combivent      0.8

Abilify was the number one drug on the Top 100 list for highest sales overall.  This is the most expensive antipsychotic drug available.  Terminal delirium and related psychoses or agitation experienced by hospice patients may often respond very well to much less expensive antipsychotic drugs such as Haloperidol or Risperidone (about  1/30th  and 1/5th  the cost of Abilify, respectively).    

There were 2 PPI’s (proton-pump inhibitors) on the list;  Nexium took the number 2 spot and Dexilant was number 56 on the Top 100.  Effective management of gastric distress in hospice patients may often be achieved with the oldest generic PPI, Omeprazole.  Omeprazole OTC is about 1/15th  the cost of these two brand name PPI’s.   

Advair and Symbicort are both long-acting beta agonist (LABA) / steroid combination inhaler drugs which are dosed twice daily.  Both are expensive. There are no low cost LABA/Steroid combination products currently available. One option for low-cost alternative therapy in hospice is to use the short-acting beta-agonist, Albuterol (four times daily), plus an oral steroid such as Prednisone 5 - 10mg daily.  Long term use of oral steroids is associated with higher incidence of side effects, however, in the hospice setting such long-term use may not be a relevant concern. The Albuterol plus Prednisone option would be about 1/10th the cost of the Advair or Symbicort.    

Two other inhaled respiratory medications on the list were Spiriva and Combivent metered dose inhalers (MDI’S).   Spiriva is an anticholinergic-type bronchodilator (tiotropium) and Combivent is the combination of the anticholinergic bronchodilator, Ipratropium, and the beta-agonist bronchodilator, Albuterol. While there is no low cost alternative to these products in metered-dose-inhaler (MDI) dosage form, there is a good low cost alternative in the nebulizer solution dosage-form of the albuterol-ipratropium combination product, also known as Duoneb (about ½ the cost of Spiriva or Combivent therapy).  

Lyrica is used for both seizure management and control of neuropathic pain in hospice patients.  A reasonable cost-effective alternative is Gabapentin which is about 1/4th  the cost of Lyrica in equivalent doses.  

Oxycontin is one of the most expensive long-acting opioids available.  Methadone is a very effective alternative at about 1/30th the cost for an equivalent dose. Methadone also has the advantage of being available in a liquid dosage-form for those patients who have difficulty swallowing whole tablets. Oxycontin tablets should not be crushed.  Morphine Extended Release tablets may also be a reasonable alternative at about 1/3 the cost of Oxycontin.  Like Oxycontin, the morphine extended release tablets should not be crushed.

Celebrex is a Cox-2 selective non-steroidal anti-inflammatory (NSAID). This is the only cox- 2 selective NSAID currently available and therefore has a distinct advantage in patients where there is significant concern or history of NSAID induced gastric side effects.   Alternatives for patients that are not in that category would in include Naproxen, Ibuprofen, and Meloxicam. These options are all about 1/10th the cost of Celebrex in equivalent doses. 

Namenda may be effective for management of cognitive symptoms encountered in moderate to severe dementia.   There is no evidence that this drug has any significant benefits in “end-stage” dementia, classified as Level 7a or greater using the FAST rating scale. By definition, a patient with a hospice diagnosis of dementia would be at Level 7a or greater, so continued therapy with Namenda would not be recommended once the patient is admitted to hospice with this diagnosis.  

Seroquel XR is the extended-release (once daily) version of the antipsychotic drug, quetiapine immediate release (twice daily). Quetiapine immediate release is available as a generic and is less expensive than the XR form with only minimal adjustment for dosage compliance (one dose per day vs two).  An even more cost-effective option is Haloperidol which is about 1/12th the cost of generic quetiapine in equivalent doses. 

Lunesta is a sedative-hypnotic which is used for management of insomnia in hospice patients.  Lunesta has recently gone generic (Eszopiclone), however, even that version is still pricey.  There are a couple of cost-effective alternatives: Temazepam (a benzodiazepine sedative hypnotic) and Trazodone (a sedating antidepressant).  Trazodone and Temazepam have been used extensively in hospice for managing insomnia with good results.  Both of these alternatives are about 1/15th the cost of Eszopiclone.  

Conclusion:  The cost-effective alternatives discussed in this article may not be appropriate for all hospice patients, and consideration of the individual patient’s drug history and comorbid conditions need to be factored into any decision to change medications.  On the other hand, each of the alternative medications suggested here have been widely used in hospice and palliative care settings for long periods of time with positive results. While not appropriate for all patients, these alternative medications should be considered as possible first-line therapies for the majority of hospice patients.  

For additional information on equivalent doses and corresponding costs, there are some helpful Hospice Medication Charts on the Outcome Resources website that provide detail about inhaled respiratory medications, PPI’s, and benzodiazepines.  You can find these under Clinical Resources in the member’s section. Outcome Resources hospice clients can also contact our clinical pharmacist staff for specific recommendations as needed.  




05/22/2014

New Wound Care Management Course added to Outcome Resources Education Portal

Dr. Jim Joyner, PharmD, CGP

I am pleased to announce that the online education section of OutcomeResources.com has been updated with a new course:  "Wound Care for Hospice Patients."  This is a very interesting and informative course that addresses the complex issues of wound management in hospice patients.  Our presenter is wound care specialist Kristen Lyn Brodrick, RN, BSN, CHPN, CWCN. The unique challenges of wound care management in hospice patients is presented through the eyes of a wound care specialist and certified hospice & palliative nurse. A description of the wound healing process sets the stage for this informative presentation, followed by a detailed discussion of the types of wounds encountered in the hospice patient.  Information about the staging of various wounds is explored. The presentation concludes with specific guidance about the role and application of various treatment modalities including a variety of wound care dressings and debridement. This program is approved by the California Board of Registered Nurses (BRN) for 1 contact hour of continuing education*. Outcome Resources partners may log on to the Members Only section of OutcomeResources.com to register for this course.

There are also two companion articles which appeared in the Outcome Resources newsletter, The Clinician, which may be of interest to those exploring this topic:

“Wound Care and the Hospice Patient:  The Perspective from a Wound Care Specialist”
Kisten Lynn Brodrick, RN, BSN, CHPN, CWCN
January 2014  Volume 9, Issue: 1

“A Discussion About Wound Care Products and Factors That Impeded Healing”
Jim Joyner, PharmD, CGP
October 2013   Volume 8,  Issue: 4  

_______________________________________________________________________________________________

Registration is now open for our Annual Conference, Pathways to Success: Conference by the Bay, which will be held November 12th-13th in Berkeley, California. An expert panel of speakers will be addressing hot topics in both clinical and administrative tracks, and you will have the opportunity to earn up to 10 contact hours of continuing education.* Learn more about this exciting hospice and palliative care conference at www.outcomeresources.com/hospice-conference.

(*Provider approved by the California Board of Registered Nursing, Provider Number 14850)




04/25/2014

Citalopram for Agitation Associated with Alzheimer’s Disease: Results of the CitAD Trial

Dr. Julia Harder, PharmD, CGP

Agitation is a common symptom experienced by hospice patients with Alzheimer’s Disease (AD), and is associated with significant distress on the part of patients, caregivers, and healthcare professionals. Current treatment options include non-pharmacologic management strategies, which are first-line but frequently insufficient, and pharmacologic strategies. The antipsychotics (such as haloperidol, risperidone and quetiapine) are the cornerstone of pharmacologic management of agitation in AD, but these medications are associated with increased mortality in elderly patients with dementia. In recent years, the use of antipsychotics for this indication has been widely discouraged by the FDA, and their use has been under scrutiny and investigation. New and better therapies for agitation associated with AD are direly needed, especially in hospice.

The Citalopram for Agitation in Alzheimer Disease (CitAD) Study was recently published in the Journal of the American Medical Association. This randomized, placebo-controlled, double-blind, parallel group trial of 186 patients with Alzheimer’s Disease and persistent moderate to severe agitation found that citalopram (at a dose of 30 mg per day) significantly reduced agitation and caregiver distress. However, this benefit was tempered by an increased risk of cardiovascular adverse effects, specifically prolongation of the cardiac QT interval.

Study participants were randomized to receive psychosocial intervention (educational materials, counseling, 24-hour crisis management) plus either citalopram or placebo for 9 weeks. Citalopram dosage began at 10 mg per day, with titration to 30 mg per day over 3 weeks based on response and tolerability. The majority of patients ended up taking the full 30 mg target dose. After the start of the study, the FDA issued its advisory that citalopram should not be prescribed at doses over 20 mg in patients older than 60 years because it causes dose-dependent QT prolongation (see our previous blog post on this topic). This advisory led the study investigators to include strict electrocardiogram (ECG) monitoring, and to exclude from the study any patients who showed QT prolongation on ECG.

At week 9 of the study, the analysis found a significant improvement in the treatment group compared with the placebo group on the 18-point Neurobehavioral Rating Scale-Agitation (NBRS-A), which assesses agitation, hostility/uncooperativeness, and disinhibition, with higher scores indicating more severe symptoms. The mean estimated treatment effect on the NBRS-A (the difference in scores at week 9, controlling for baseline score and MMSE score) was –0.93 (95% confidence interval, –1.80 to –0.06; P = .04).

In addition, 40% of the patients receiving citalopram had moderate or marked improvement from baseline severity on the 7-point modified Alzheimer's Disease Cooperative Study–Clinical Global Impression of Change score, which assesses items specific to agitation in AD. This compared to 26% of the patients taking placebo.

According to the study’s lead investigator, Dr. Anton Porsteinsson, this effect of citalopram on agitation is about the same as that of atypical antipsychotic drugs, such as quetiapine and risperidone.

The downside is that patients in the treatment group did show QT prolongation (18.1 ms; 95% CI, 6.1-30.1; P = .01) compared to the placebo group. "Our findings support the FDA," said Dr. Porsteinsson. "If nonpharmacological intervention is not beneficial, judicious use of citalopram appears to have a role in managing agitation in patients with Alzheimer's disease, but generally, the dose should not surpass 20 mg per day."

The study didn't include enough patients taking 20 mg of citalopram to determine whether this dose affected the QT interval or whether it also led to reduced agitation. So, next on the research agenda is applying for funding to look at 20 mg as the target dose, said Dr. Porsteinsson. "The aim is to treat people with clinically meaningful agitation and see if that dose has similar agitation efficacy and if it reduces caregiver burden to the same degree, but without the QTc findings.”

Reference
Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial. JAMA 2014;311:682-691.

Photo Credit




04/04/2014

FDA Approves Evzio® (Naloxone Hand-Held Auto-Injector) For Opioid Overdose

Dr. Julia Harder, PharmD, CGP

Drug overdose deaths, driven largely by prescription drug overdose deaths, are now the leading cause of injury death in the United States – surpassing motor vehicle crashes. Opioid overdose, in particular, has been steadily rising over the past decade, and has been the subject of intense FDA focus and regulation.

As we know, naloxone is an opioid receptor antagonist that rapidly reverses the effects of opioid overdose and is the standard of care. However, existing naloxone drugs require intravenous administration and are most commonly used by trained medical personnel in emergency departments and ambulances.

Yesterday, the FDA approved Evzio (naloxone HCl injection, manufactured by Kaleo, Inc.) for the emergency treatment of known or suspected opioid overdose. Evzio is a hand-held auto-injector that rapidly delivers a single 0.4 mg dose of naloxone as an intramuscular or subcutaneous injection into the thigh. The auto-injector, which is about the size of a cell phone, can be carried in a pocket or stored in a medicine cabinet, to be used by family members or caregivers in the case of suspected opioid overdose, as manifested by respiratory and/or central nervous system depression (e.g., extreme sedation or loss of consciousness). Evzio is approved for use in adult and pediatric patient (even infants).

Evzio is not intended to be a substitute for immediate medical care. The duration of action of most opioids exceeds that of naloxone, meaning that respiratory and/or CNS depression may recur after an initial improvement in symptoms. Therefore, the administrator should always seek immediate medical attention after giving the first dose of Evzio, and should repeat doses of Evzio every 2-3 minutes, depending on the patient’s response, while waiting for emergency medical assistance.

Evzio was reviewed under the FDA's priority review program and was also granted a fast track designation. Evzio is expected to be available this summer as a carton containing 2 prefilled auto-injectors and a single Trainer injector.




03/25/2014

Vortioxetine (Brintellix™): A New Multimodal Antidepressant and its Place in Hospice Care

Dr. Julia Harder, PharmD, CGP

On September 30, 2013, a new antidepressant, vortioxetine (Brintellix™ -- Lundbeck and Takeda), was approved by the FDA. Vortioxetine is considered a “multimodal antidepressant”, which puts it in a class of its own. This blog post will summarize important points about the clinical use of vortioxetine, especially in the hospice population, in whom depression is very common.

Mechanism of Action

Vortioxetine is thought to work through a combination of both serotonin reuptake inhibition and serotonin receptor activity, including agonism at the 5-HT1A receptor and antagonism at the 5-HT3 receptor. As a result of this multimodal and partially novel mechanism of action, vortioxetine may hold promise for patients who have failed to respond to first-line treatment options. Vortioxetine may also have beneficial effects on cognition, which is currently being investigated further.

Efficacy Data

Data from both short- and long-term randomized controlled trials (RCTs) have demonstrated vortioxetine’s efficacy both in the treatment of major depression and in preventing relapse. International data have shown significant efficacy of vortioxetine in a dose range from 5 to 20 mg/day but most consistently at doses of 10-20 mg/day. Two low-dose studies, (2.5 mg/day and 5 mg/day of vortioxetine) did not show superiority over placebo. Furthermore, antidepressant efficacy has been demonstrated specifically in an elderly population (mean age, 70.6 years), which is unique among the antidepressants. An RCT of more than 450 elderly adults with major depressive disorder from 7 countries showed that those treated with vortioxetine showed significantly greater improvement on several depression rating scales and cognitive tests compared with those who received placebo.

Vortioxetine has also shown efficacy in patients who have already failed a first-line antidepressant. The REVIVE study compared the efficacy of vortioxetine with the most recently approved novel antidepressant in Europe, agomelatine, in a well-powered, head-to-head trial. Of note, the patients were non- or partial responders with a history of at least 6 weeks of treatment with an SSRI or SNRI who were then abruptly switched to 12 weeks of randomized treatment with either vortioxetine (10-20 mg/day) or agomelatine. In this "out of class" switch strategy for patients with insufficient response to first-line antidepressants, vortioxetine led to significantly greater improvement in depression scores at 8 weeks compared with agomelatine, with similar effects at week 12.

Finally, on the basis of its mechanism of action, vortioxetine is being studied for potentially beneficial effects on cognition. Initial data on the potentially procognitive effects of vortioxetine, independent of the drug's effects on symptoms of depression, have been generated in elderly patients with major depressive disorder. Other studies with cognition as a primary outcome are ongoing.

Safety Data

The most common adverse effects of vortioxetine across multiple studies were nausea, diarrhea, dry mouth, sweating, and headache – standard antidepressant side effects. Of these, nausea seems to be the most common. The potential benefits of vortioxetine include low rates of sedation/somnolence and insomnia, low weight gain in both short- and long-term studies, and less sexual side effects than the SSRIs.

Like other antidepressant medications, vortioxetine has an FDA boxed warning and a medication guide alerting patients and healthcare professionals that antidepressants can increase the risk for suicidal thought and behavior in children, adolescents, and young adults aged 18 to 24 years during initial treatment.

Dose

The recommended starting dose is 10 mg orally once daily, taken at any time and without regard to food intake. The dose should then be increased to 20 mg/day, as tolerated, with consideration being given to lowering the dose to 5 mg/day for patients who do not tolerate higher doses. Vortioxetine is currently available as brand-name only (Brintellix™), in 5 mg, 10 mg, and 20 mg tablets.

Pharmacokinetics

Vortioxetine has a favorable pharmacokinetic profile. It is metabolized by several different liver enzymes (rather than predominantly just one or two), which means that is does not have many drug interactions beyond the normal ones we are familiar with (tramadol, linezolid, methylene blue, monoamine oxidase inhibitors, triptans) that interact with all serotonergic antidepressants. Vortioxetine also has a long half-life of about 60 hours, which means that rebound or withdrawal will be unlikely if patients miss doses or have to abruptly discontinue the medication due to the loss of swallowing ability.

Cost

Currently, Brintellix™ is one of, if not the, most expensive antidepressants on the market, with an average wholesale price of $8.72 per tablet (same price for all strengths). By comparison, levomilnacipran (Fetzima™, another new antidepressant approved in 2013 that is still brand only) is $8.10 per tablet, escitalopram is about $4.50 per tablet, and citalopram is about $2.50 per tablet.

Place in Hospice Therapy

Vortioxetine has many positive characteristics, including a multimodal mechanism of action, demonstrated efficacy in the elderly, favorable pharmacokinetics, and a relatively short list of side effects. However, because of lack of clinical experience and very high cost, vortioxetine should not be used as a first-line agent for the treatment of depression in hospice. As a result of the diverse and partially novel mechanism of action of vortioxetine, this new multimodal antidepressant may hold promise for a very select group of hospice patients, including:

• Patients who have tried and failed other first-line therapies, including one or more SSRIs
• Patients who have experienced intolerable sedation/somnolence or insomnia with other antidepressants
• Patients with comorbid cognitive deficits

The broader picture of vortioxetine's clinical utility and place in the treatment of patients with depression will need to be established through its clinical use after approval and ongoing and future phase 4 trials. Future studies will hopefully examine whether vortioxetine has more robust efficacy in certain patient subgroups, including treatment-nonresponsive/resistant patients and those with comorbid cognitive problems, as this would be of particular interest to the hospice community.

 




03/19/2014

CMS, Medicare Part D, and the Hospice Medication Coverage Debacle

Dr. Julia Harder, PharmD, CGP

CMS issued final guidance on the subject of Part D Payment for Drugs for Beneficiaries Enrolled in Hospice on March 10th, 2014. (Click to Download the full CMS Memo.) In this blog post, we will summarize the CMS memo and highlight the important points that you and your hospice need to know in order to most effectively sort through the mess that medication coverage has become in recent months.

 

Background

On December 6, 2013, CMS issued a memorandum to all Part D plan sponsors and hospice providers clarifying the criteria for determining payment responsibility for drugs for hospice beneficiaries. In the memo, they stated: “In order for services to be covered under the Medicare hospice benefit, those services must be reasonable and necessary for the palliation and management of the terminal illness and related conditions. … To the extent that individuals seek and receive services outside of the hospice program, Medicare coverage is determined by whether or not the services are for treatment of a condition completely unrelated to the individual’s terminal condition. It is our general view that the statutory waiver of the right to payment of standard Medicare benefits for treatment of the terminal illness and related conditions is a broad one, and hospices are required to provide virtually all the care that is needed by terminally ill individuals. … Beneficiaries should only very rarely be taking drugs that are not covered under the hospice per diem.”

CMS urged Part D plan sponsors to “place beneficiary-level PA [prior authorization] requirements on all drugs for hospice beneficiaries to determine whether the drugs are coverable under Part D.” They went on to say that “The hospice provider will be responsible for coordinating with Part D plan sponsors for those drugs they believe are completely unrelated to the terminal illness and/or related conditions”. In such instances, CMS expects that “the hospice provider or prescriber will immediately provide, to the Part D sponsor, the written documentation necessary to satisfy the PA.”

In other words, CMS stated that hospices should be covering virtually all of a patient’s medications. Part D plans were instructed to reject outright any claim for a beneficiary enrolled in hospice and to use a prior authorization process for the very rare occasion that a beneficiary would be taking a medication not covered by the hospice per diem. CMS initially set an effective date of March 1, 2014.

Hospices and anyone affiliated with them have been in an uproar about this issue, as CMS’s memo is in clear disagreement both with the longstanding statutory and regulatory framework that has been in place since the inception of the Medicare hospice benefit, and with the clinical reality of hospice patients. Individual stakeholders and organizations such as the National Hospice and Palliative Care Organization (NHPCO) have lobbied tirelessly on behalf of hospice providers, asking CMS for clarification on many points and to reconsider implementation of this directive. CMS remained silent on the issue until March 10, 2014, 9 days after their initial implementation date of March 1, at which time many hospice pharmacies were already receiving rejected claims from Part D plan sponsors.

The March 10, 2014 Memo

On Monday, March 10, CMS issued the “Part D Payment for Drugs for Beneficiaries Enrolled in Hospice – Final 2014 Guidance.” This new memo reinforced many of the statements CMS made back in December of last year. The memo states: “We expect drugs covered under Part D for hospice beneficiaries will be unusual and exceptional circumstances”, and continues to recommend that the Part D plan sponsors place beneficiary-level PA requirements on ALL drugs for hospice patients. However, CMS did make some further clarifications and concessions. The following is a list of the most important points from CMS’s memo (however, we highly encourage that you read the memo in its entirety).

1. The implementation date was moved back to May 1, 2014 (although some Part D plans have already initiated the prior authorization process based on CMS’s earlier memo, and they are permitted to do so).

2. There is currently no standard PA form that CMS will require the Part D plans to use. However, CMS did compile a list of elements they would expect to see on a PA form, which can be found on pages 13-14 of the attached memo. Some Part D sponsors may choose to adopt that information list as their PA form. The best way to retrieve any particular Part D plan’s PA form is to contact them directly.

3. If the patient does not know who their Part D sponsor is, hospice providers can find that information through the patient’s primary pharmacy (NOT the PBM, but the dispensing pharmacy). Pharmacies can identify a beneficiary’s Part D plan by submitting a standard electronic eligibility (E1) query to the CMS Transaction Facilitator. The query response will give the name of the plan sponsor, the sponsor’s online billing information, and the sponsor’s pharmacy help desk telephone number.

4. Hospice providers may initiate the PA process prospectively (prior to the submission of any claims, such as upon initial hospice election) by initiating communication with the Part D provider, providing an explanation of why certain drugs are unrelated to the terminal illness, and submitting any necessary documentation. This proactive approach could speed up the process by avoiding rejected claims. This would also notify the part D sponsor right away of the patient’s hospice election, so that the Part D plan doesn’t continue to pay claims and then have to recoup those payments later.

5. Hospices may also initiate the PA process after a claim has been rejected. The rejection message will state “Hospice Provider- Request Prior Authorization for Part D Drug Unrelated to the Terminal Illness or Related Conditions” and should include the Part D sponsor’s 24-hour pharmacy help desk phone number. The pharmacy would contact the prescriber to pass along this information. The prescriber must then call the Part D plan to initiate the PA process. PAs can be completed either verbally or in writing. The hospice may provide a verbal explanation to the sponsor regarding why the drug is unrelated to the terminal illness or related conditions, or may complete the PA form and fax it to the sponsor. Hospices should be aware that the turn-around time for a PA is 24 hours for an expedited request and 72 hours for a standard request, with the clock starting once the Part D plan sponsor has received the completed PA from the hospice (either verbally or in writing).

6. In the case that a medication is prescribed by someone unaffiliated with the hospice (such as the patient’s primary physician), the prescriber and the hospice will need to coordinate their efforts. Either individual may complete the PA; if the prescriber unaffiliated with hospice completes the PA, the prescriber will need to attest that he or she has coordinated with the hospice provider and that the hospice provider concurs with the unrelated nature of the drug.

As mentioned before, many Part D plans are already starting to reject claims, so it is crucial that hospices become familiar with this issue and begin to develop procedures for incorporating this new PA process into their daily workflow. NHPCO has created an excellent Compliance Tool, “Incorporating Medicare Pare D into the Hospice Admissions and Medication Management Process.” We suggest that you download this document for assistance with how to implement this new CMS policy.

We look forward to your questions and comments on this highly controversial issue.
 




First 10 <<Previous 10 Next 10 >> Last 10

 

 


Education Resources and Support for Hospices

Stay up-to-date on the latest hospice pharmacy benefits management information and tools with a variety of education resources and support at no extra charge. We offer presentations live at your facility, over the Internet or viaEducational Resources and Support for Hospicesteleconference, online service education programs, customized courses, and courses accredited for nursing continuing education credit.

See all of our educational resources>>

Clinical hospice and palliative cae consultation

Clinical Services

Our palliative care experts provide clinical consulting on important medication management and care decisions. Our non-dispensing pharmacists provide focused attention and unbiased advice.

 

Read more about our clinical pharmacy benefits management services>>

Why Use A PBM?

Contracting with multiple pharmacies, doing all the reporting, trying to stay current with medical practices and stay compliant while keeping costs down? There’s an easier and more effective way.

Find out how using a pharmacy benefits manager (PBM) can help you>>

Why Use a PBM